{"title":"Clinical and imaging characteristics of patients with axial psoriatic arthritis: Baseline findings from the GESPIC-axial-PsA cohort.","authors":"Henriette Baum, Murat Torgutalp, Valeria Rios Rodriguez, Judith Rademacher, Mikhail Protopopov, Hildrun Haibel, Burkhard Muche, Kay-Geert Hermann, Denis Poddubnyy, Fabian Proft","doi":"10.1177/1759720X261472985","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Axial disease is a domain of psoriatic arthritis (PsA), referred to as axial-PsA. Despite recent advances and increasing recognition, axial-PsA remains poorly defined; validated classification criteria and longitudinal cohorts are lacking.</p><p><strong>Objectives: </strong>We aimed to characterise axial-PsA and delineate phenotypes in an imaging-confirmed cohort.</p><p><strong>Design: </strong>GESPIC-axPsA, a dedicated arm of the German Spondyloarthritis Inception Cohort (GESPIC), is a prospective, monocentric, study including patients with psoriasis and clinically diagnosed axial-PsA confirmed by imaging. Baseline assessments included clinical phenotyping, laboratory testing, biosample-collection, radiographs of the axial skeleton, and MRI of the whole spine and sacroiliac joints (SIJs).</p><p><strong>Methods: </strong>The analysis was primarily descriptive, characterizing baseline clinical and imaging features of patients with imaging-confirmed axial-PsA; categorical and continuous variables were summarized using appropriate measures based on their distribution, and subgroup comparisons were performed using chi-square or Fisher's exact tests for categorical variables and Mann-Whitney U tests for continuous variables after assessing normality.</p><p><strong>Results: </strong>We enrolled 107 axial-PsA patients (55% female; mean age 44.8 years); 78.5% had active psoriasis, 78.6% had inflammatory back pain (IBP), and 48.6% were HLA-B27 positive. Radiographic sacroiliitis was present in 45.7%. On MRI, active/structural SIJ lesions were seen in 53.3%/73.3%; spinal active/structural lesions in 60.0%/53.3%. Both Classification criteria for axSpA (ASAS) and PsA (CASPAR) were simultaneously fulfilled in 60.7%. We identified 20 patients (18.7%) with spine-only involvement-spinal MRI lesions without SIJ lesions on radiography or MRI. Compared with the remainder, the spine-only group was older, more often female, less frequently HLA-B27-positive, and had back pain less consistent with IBP (all p<0.05).</p><p><strong>Conclusions: </strong>In our imaging-confirmed axial-PsA cohort using standardized whole-spine and SIJ MRI, we observed marked phenotypic heterogeneity. Approximately one fifth had isolated spinal involvement; this subgroup differed by age, sex, HLA-B27, and IBP features, with imaging distributions distinct from axSpA-supporting the need for disease-specific classification criteria.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"18 ","pages":"1759720X261472985"},"PeriodicalIF":3.3000,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13546424/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Musculoskeletal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1759720X261472985","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Axial disease is a domain of psoriatic arthritis (PsA), referred to as axial-PsA. Despite recent advances and increasing recognition, axial-PsA remains poorly defined; validated classification criteria and longitudinal cohorts are lacking.
Objectives: We aimed to characterise axial-PsA and delineate phenotypes in an imaging-confirmed cohort.
Design: GESPIC-axPsA, a dedicated arm of the German Spondyloarthritis Inception Cohort (GESPIC), is a prospective, monocentric, study including patients with psoriasis and clinically diagnosed axial-PsA confirmed by imaging. Baseline assessments included clinical phenotyping, laboratory testing, biosample-collection, radiographs of the axial skeleton, and MRI of the whole spine and sacroiliac joints (SIJs).
Methods: The analysis was primarily descriptive, characterizing baseline clinical and imaging features of patients with imaging-confirmed axial-PsA; categorical and continuous variables were summarized using appropriate measures based on their distribution, and subgroup comparisons were performed using chi-square or Fisher's exact tests for categorical variables and Mann-Whitney U tests for continuous variables after assessing normality.
Results: We enrolled 107 axial-PsA patients (55% female; mean age 44.8 years); 78.5% had active psoriasis, 78.6% had inflammatory back pain (IBP), and 48.6% were HLA-B27 positive. Radiographic sacroiliitis was present in 45.7%. On MRI, active/structural SIJ lesions were seen in 53.3%/73.3%; spinal active/structural lesions in 60.0%/53.3%. Both Classification criteria for axSpA (ASAS) and PsA (CASPAR) were simultaneously fulfilled in 60.7%. We identified 20 patients (18.7%) with spine-only involvement-spinal MRI lesions without SIJ lesions on radiography or MRI. Compared with the remainder, the spine-only group was older, more often female, less frequently HLA-B27-positive, and had back pain less consistent with IBP (all p<0.05).
Conclusions: In our imaging-confirmed axial-PsA cohort using standardized whole-spine and SIJ MRI, we observed marked phenotypic heterogeneity. Approximately one fifth had isolated spinal involvement; this subgroup differed by age, sex, HLA-B27, and IBP features, with imaging distributions distinct from axSpA-supporting the need for disease-specific classification criteria.
期刊介绍:
Therapeutic Advances in Musculoskeletal Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of musculoskeletal disease.